More tools:Markets·Screener·Research·Chat

ImmunityBio, Inc. Common Stock (IBRX) Financial Statements

ImmunityBio, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG007T9DYX8
XNAS · usd
8.29▲ 0.21 (2.60%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close8.08
Day's Range7.93 – 8.37
52-Week Range1.95 – 12.43
Volume7.7M
Avg Volume8.2M
Share Statistics
Shares Outstanding
Employees691
ExchangeXNAS
Listed2021-03-10
Share count as of July 31, 2026
Loading Income Statement…
Key questions about ImmunityBio, Inc. Common Stock (IBRX)
What is ImmunityBio, Inc. Common Stock's Market Cap?
ImmunityBio, Inc. Common Stock's Market Cap is $8.8B, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's Enterprise Value?
ImmunityBio, Inc. Common Stock's Enterprise Value is $8.4B, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's Price / Sales?
ImmunityBio, Inc. Common Stock's Price / Sales is 53.0×, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's EV / Revenue?
ImmunityBio, Inc. Common Stock's EV / Revenue is 50.8×, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's EV / EBITDA?
ImmunityBio, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's Revenue (TTM)?
ImmunityBio, Inc. Common Stock's Revenue (TTM) is $165.8M, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's Net Income (TTM)?
ImmunityBio, Inc. Common Stock's Net Income (TTM) is -$992.4M, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's EBITDA?
ImmunityBio, Inc. Common Stock's EBITDA is -$235.2M, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's Diluted EPS (TTM)?
ImmunityBio, Inc. Common Stock's Diluted EPS (TTM) is -0.94, based on as-reported figures from SEC (XBRL) filings.
What is ImmunityBio, Inc. Common Stock's EBITDA Margin?
ImmunityBio, Inc. Common Stock's EBITDA Margin is -141.9%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenue
YoY growth+93.9%+167.6%+407.0%+425.1%
Operating costs and expenses
Cost of sales
Research and development
Selling, general and administrative
Total operating costs and expenses
% of revenue220.4%257.9%269.0%273.5%
Loss from operations
% of revenue-120.4%-157.9%-169.0%-173.5%
Other income (expense), net
Interest and investment income, net
Change in fair value of related-party convertible note
Change in fair value of warrant liabilities
Interest expense related to revenue interest liability
Interest expense
Change in fair value of derivative liabilities
Other income (expense), net
Total other expense, net
Loss before income taxes and noncontrolling interest
Income tax expense
Net loss
% of revenue-449.6%-1431.5%-161.8%-209.8%
Net loss attributable to noncontrolling interests, net of tax
Net loss attributable to ImmunityBio common stockholders
% of revenue-449.6%-1431.4%-161.8%-209.8%
Net loss per ImmunityBio common share – basic (in dollars per share)
Net loss per ImmunityBio common share - diluted (in dollars per share)